<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890708</url>
  </required_header>
  <id_info>
    <org_study_id>H-0808-057-254</org_study_id>
    <nct_id>NCT00890708</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of Voriconazole</brief_title>
  <official_title>Influence of Therapeutic Drug Monitoring of Voriconazole on Incidence of Drug Adverse Reaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether therapeutic drug monitoring of voriconazole
      is useful in the treatment of invasive fungal infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Voriconazole is an anti-fungal agent, which is used in the treatment of invasive fungal
      infection, especially aspergillosis. The serious side effects of voriconazole include liver
      function abnormality, encephalopathy, etc. Recently, the several studies showed that the
      blood level of voriconazole is variable and it is associated with drug side effect and
      treatment outcome. However, there is no randomized controlled study which proves that
      therapeutic drug monitoring of voriconazole can improve the clinical outcome in routine
      clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>side effects</measure>
    <time_frame>during 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment response to voriconazole</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug discontinuation of adverse events</measure>
    <time_frame>within 3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>non-TDM of voriconazole</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDM of voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole (therapeutic drug monitoring)</intervention_name>
    <description>dosage adjustment according to trough level of voriconazole in plasma</description>
    <arm_group_label>TDM of voriconazole</arm_group_label>
    <other_name>plasma drug level</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who were 16 years of age or older

          -  receiving voriconazole in order to treat invasive fungal infections or for empirical
             use

        Exclusion Criteria:

          -  who experienced the serious side effect of voriconazole

          -  were hypersensitive to azoles

          -  had an aminotransferase, bilirubin, or alkaline phosphatase level higher than five
             times the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan Beom Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <last_update_submitted>February 18, 2012</last_update_submitted>
  <last_update_submitted_qc>February 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Wan Beom Park</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

